Navigation Links
Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
Date:11/14/2011

ROCKVILLE, Md., Nov. 14, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the ongoing Phase I trial to test its spinal cord stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) was featured Wednesday night on Fox 5 News in Atlanta  http://www.neuralstem.com/neuralstem-in-the-news

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The trial was recently approved by the FDA to advance to cervical injections.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has completed an FDA-approved Phase Ia safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depression, and expects to receive Phase Ib trial approval in the fall.  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010 and the  quarterly report on Form 10-Q for the period ended September 30, 2011.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Reports Second Quarter Financial Results and Highlights
2. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
3. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
4. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Neuralstem, Inc.
6. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
7. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
8. Neuralstem Completes $5.25 Million Financing
9. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
10. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
11. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... , ... Having worked on the design of the innovative Triton™ lab ... top lab design architects from around the country at the Lab Design Conference 2017 ... Engineering Greg Casey will be at the show, where they will highlight the unique ...
(Date:4/21/2017)... BELLINGHAM, Washington, USA (PRWEB) , ... April 21, ... ... for sensing, imaging, and related applications were the focus of researchers, engineers, product ... Sensing 2017 in Anaheim. , Sponsored by SPIE, the international society ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology ... of emerging bio and technology start-ups, is hosting “Celebration Friday” (a festive gathering ... will start with libations and networking at 3:30 p.m. at FITCI’s 4539 Metropolitan ...
(Date:4/20/2017)... Yorba Linda, Ca (PRWEB) , ... April 20, ... ... Virtual University Virtual Event , this new webinar will explore challenging patient cases ... are admitted to the hospital, there may be a need for bridging parental ...
Breaking Biology Technology:
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):